Among the therapies it is developing are 177Lu-satoreotide tetraxetan for neuroendocrine tumors, small cell lung cancer, Merkel Cell Carcinoma, and solid tumors; ATT001, which is due to begin Phase I development for the treatment of glioblastoma; ATD001, a fluorine-18 radiolabeled rPARPi currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center for head and neck cancer; and ATT002 as an alpha and beta therapy.

Its diagnostics pipeline includes NEPHROSCAN, a single-dose kit for the preparation of technetium-99m (Tc-99m) Succimer for renal parenchymal disorders; androgen deprivation therapy for prostate cancer; 68Ga-satoreotide trizoxetan for solid tumors; ATD001 for solid tumors; satoreotide tetraxetan for neuroblastomas.


Ariceum has expanded and established its workforce ahead of the lab opening and will recruit additional employees as the company grows. While most early-stage R&D activities will be performed in-house, Ariceum will continue to use external partners for certain aspects of its research and development.

Back to HCB News

Molecular Imaging Homepage